By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



300 George Street

New Haven  Connecticut  06511  U.S.A.
Phone: 203-848-1234 Fax: 203-848-6007



Company News
ZIOPHARM, Inc. Reports Second-Quarter 2014 Financial Results And Reviews Recent Activities 8/8/2014 10:47:32 AM
ZIOPHARM, Inc. Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update 7/22/2014 3:18:52 PM
ZIOPHARM, Inc. Announces FDA Acceptance of IND for Oral Palifosfamide 2/6/2012 9:52:18 AM
ZIOPHARM, Inc. Granted European Patent Allowance for Palifosfamide 12/7/2011 6:23:44 AM
ZIOPHARM, Inc. Oncology Presents New Darinaparsin Preclinical Prostate and Pancreatic Cancer Data at American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer Meeting 11/16/2011 6:08:14 AM
ZIOPHARM, Inc. Presents Preclinical Data for Darinaparsin Effect on Hedgehog Signaling Pathway in Prostate Cancer at AACR-NCI-EORTC Meeting 11/14/2011 9:47:06 AM
ZIOPHARM, Inc. Reports Third Quarter Financial Results and Highlights 11/4/2011 6:29:29 AM
ZIOPHARM, Inc. Presents Promising Preclinical Pediatric Sarcoma Data with Oral and IV Palifosfamide at the 2011 CTOS/MSTS Meeting 10/28/2011 11:17:59 AM
ZIOPHARM, Inc. to Present at Upcoming Investor Conferences 9/20/2011 9:14:05 AM
ZIOPHARM, Inc. Seeks Lower Cancer Drug Prices 6/2/2011 7:13:32 AM